Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: MEDI4736 (Anti PD-L1)|DRUG: Placebo|DRUG: nab-Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: German Breast Group
Collaborators: AstraZeneca|Celgene